IL6 Promotes a STAT3-PRL3 Feedforward Loop via SHP2 Repression in Multiple Myeloma

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Overexpression of the oncogenic phosphatase PRL-3 is a novel finding in multiple myeloma.
• The precise regulatory mechanisms and oncogenic functions of PRL-3 in multiple myeloma require further elucidation.

Purpose of the Study:

• To investigate the regulation of PRL-3 by IL6-activated STAT3 in multiple myeloma.
• To elucidate the role of PRL-3 in myeloma cell viability, survival, and resistance to therapy.

Main Methods:

• Investigated the IL6-STAT3-PRL-3 signaling axis using molecular biology techniques.
• Assessed the impact of PRL-3 modulation on myeloma cell proliferation, apoptosis, and drug resistance.
• Analyzed STAT3 and PRL-3 expression correlation in patient cohorts.

Main Results:

• IL6 activates STAT3, which directly upregulates PRL-3 transcription.
• PRL-3 enhances myeloma cell viability and survival by rephosphorylating STAT3 and deactivating SHP2.
• PRL-3 silencing reduced tumor growth, overcame bortezomib resistance, and decreased STAT3 target gene expression.

Conclusions:

• A positive feedback loop exists between STAT3 and PRL-3, sustaining prosurvival signaling in multiple myeloma.
• PRL-3 is a potential therapeutic target and a biomarker for identifying high-risk multiple myeloma patients.